Antibiotics have been vital in saving lives for over 80 years, yet the rise of antimicrobial resistance (AMR) threatens their efficacy, causing approximately 1.27 million deaths globally in 2019. If unchecked, AMR could result in 10 million deaths annually by 2050. In response, Indian pharmaceutical company Wockhardt has developed Zaynich, a pioneering antibiotic and the first new chemical entity fully designed and approved by the US drug regulator from India. This achievement underscores India's growing role in innovative drug development, particularly following changes to patent laws in 2005 that protect new inventions. While India faces stiff competition from China, which contributes to about 25% of new drug candidates, its historical capabilities in scientific innovation, exemplified by Upendranath Brahmachari's success in treating kala-azar, suggest a promising future for India's pharmaceutical industry. With continued government support and incentives, India could emerge as a leader in creating life-saving medicines.